News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Louisville's GlobeImmune, Inc. Reduces Size Of Proposed IPO


5/22/2014 7:51:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Louisville-based GlobeImmune Inc. has reduced the size of its proposed initial public offering by $10 million, according to a filing made Wednesday with the U.S. Securities and Exchange Commission. GlobeImmune, a biopharmaceutical firm developing drugs to treat cancers and infectious diseases, now plans to offer 1,562,500 shares, down from 2,187,500 shares. The pricing remained in the $15 to $17 range.

Help employers find you! Check out all the jobs and post your resume.

Read at Daily Camera
Read at Nasdaq
Read at Denver Business Journal

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES